Human CD25/IL-2R alpha Antibody
R&D Systems, part of Bio-Techne | Catalog # MAB223
Key Product Details
Species Reactivity
Validated:
Human
Cited:
Human, Feline
Applications
Validated:
Immunocytochemistry, Neutralization, Western Blot
Cited:
Bioassay, Flow Cytometry, Neutralization
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # 22722
Product Specifications
Immunogen
S. frugiperda insect ovarian cell line Sf 21-derived recombinant human CD25/IL-2 R alpha
Glu22-Cys213
Accession # P01589
Glu22-Cys213
Accession # P01589
Specificity
Detects human CD25/IL-2 R alpha in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 4% cross-reactivity with recombinant human (rh) IL-2 R beta is observed and no cross-reactivity with rhIL-2 R gamma, rhIL-1 RI, rhIL-1 RII, rhIL-4 R, rhIL-5 R alpha, rhIL-6 R, rhIL-7 R, rhIL-9 R, and rhIL-10 R is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Scientific Data Images for Human CD25/IL-2R alpha Antibody
CD25/IL‑2 R alpha in Human PBMCs.
CD25/IL-2 Ra was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with PHA and monensin using Mouse Anti-Human CD25/IL-2 Ra Monoclonal Antibody (Catalog # MAB223) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (yellow; Catalog # NL007) and counterstained with DAPI (blue). View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
Cell Proliferation Induced by IL‑2 and Neutralization by Human CD25/IL‑2 R alpha Antibody.
Recombinant Human IL-2 (Catalog # 202-IL) stimulates proliferation in the N1186 human T cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Human IL-2 (1 ng/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human CD25/IL-2 Ra Monoclonal Antibody (Catalog # MAB223). The ND50 is typically 0.5-1.0 µg/mL.Applications for Human CD25/IL-2R alpha Antibody
Application
Recommended Usage
Immunocytochemistry
8-25 µg/mL
Sample: Immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with PHA and monensin
Sample: Immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with PHA and monensin
Western Blot
1 µg/mL
Sample: Recombinant Human CD25/IL‑2 R alpha (Catalog # 223-2A) under non-reducing conditions only
Sample: Recombinant Human CD25/IL‑2 R alpha (Catalog # 223-2A) under non-reducing conditions only
Neutralization
Measured by its ability to neutralize IL-2-induced proliferation in the N1186 human T cell line. The Neutralization Dose (ND50) is typically 0.5-1.0 µg/mL in the presence of 1 ng/mL Recombinant Human IL-2.
Reviewed Applications
Read 1 review rated 3 using MAB223 in the following applications:
Formulation, Preparation, and Storage
Purification
Protein A or G purified from ascites
Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD25/IL-2R alpha
Long Name
Interleukin 2 Receptor alpha
Alternate Names
CD25, IL-2 R alpha, IL-2Ra, IL2R alpha, IL2RA
Entrez Gene IDs
Gene Symbol
IL2RA
UniProt
Additional CD25/IL-2R alpha Products
Product Documents for Human CD25/IL-2R alpha Antibody
Product Specific Notices for Human CD25/IL-2R alpha Antibody
For research use only
Loading...
Loading...
Loading...
Loading...